Embed

Academic

Authors

Rudolf Morant

Rudolf Morant,Kantonsspital Saint Gallen,Oncology,Anatomy,Pharmacology

Edit

Rudolf Morant

Kantonsspital Saint Gallen

Publications: 56 | Citations: 914

Fields: Oncology, Anatomy, Pharmacology

Collaborated with 225 co-authors from 1989 to 2009 | Cited by 3548 authors

Cumulative Annual

Sort by:

Publications (56)

BibTeX | RIS | RefWorks Download

Cyclosporin-A therapy of pure red cell aplasia in a patient with B-cell chronic lymphocytic leukemia (Citations: 3)

, ,

Journal: European Journal of Haematology - EUR J HAEMATOL , vol. 42, no. 3, pp. 303-307, 2009

0070 Hormone receptors and HER2 status can change in recurrent breast cancer

, , , , , , ,

Journal: Breast , vol. 18, pp. S36-S36, 2009

Chemoprevention of breast and prostate cancers: where do we stand? (Citations: 2)

Journal: Annals of Oncology - ANN ONCOL , vol. 19, no. Supplement, pp. vii234-vii237, 2008

Quality of analgesic treatment in patients with advanced prostate cancer: do we do a better job now? The Swiss Group for Clinical Cancer Research (SAKK) experience (Citations: 1)

, , , ,

Journal: Supportive Care in Cancer - SUPPORT CARE CANCER , vol. 16, no. 5, pp. 461-467, 2008

Planung und Durchführung klinischer Phase-III-Studien

Journal: Onkologie , vol. 31, no. 2, pp. 53-57, 2008

Sort by:

Citations (914 times by 886 publications)

A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study

, , , , , , , , ,

Journal: Prostate Cancer and Prostatic Diseases - PROSTATE CANCER PROSTATIC DIS , vol. 15, no. 1, pp. 87-92, 2012

Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells

, , , , , , , , , , , http://academic.research.microsoft.com/io.ashx?type=5&id=56544131&selfId1=8074304&selfId2=0&maxNumber=12&query=

Journal: Cell Death and Disease , vol. 3, no. 1, 2012

Epigenetic regulation in RCC: opportunities for therapeutic intervention?

, , , ,

Journal: Nature Reviews Urology - NAT REV UROL , vol. 9, no. 3, pp. 147-155, 2012

Improving the efficacy of targeted trials by multiple-marker analysis in castration-resistant prostate cancer (Citations: 1)

, , , , , ,

Journal: Urologic Oncology-seminars and Original Investigations , vol. 29, no. 6, pp. 664-669, 2011

Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting (Citations: 2)

, ,

Journal: Supportive Care in Cancer - SUPPORT CARE CANCER , vol. 19, no. 1, pp. 131-140, 2011

Comments

Co-authors (225)

Journals (20)

Keywords (179)

Rudolf Morant,Kantonsspital Saint Gallen,Oncology,Anatomy,Pharmacology

Publications (56)

BibTeX | RIS | RefWorks Download

Cyclosporin-A therapy of pure red cell aplasia in a patient with B-cell chronic lymphocytic leukemia (Citations: 3)

0070 Hormone receptors and HER2 status can change in recurrent breast cancer

Chemoprevention of breast and prostate cancers: where do we stand? (Citations: 2)

Quality of analgesic treatment in patients with advanced prostate cancer: do we do a better job now? The Swiss Group for Clinical Cancer Research (SAKK) experience (Citations: 1)

Planung und Durchführung klinischer Phase-III-Studien

Citations (914 times by 886 publications)

A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study

Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells

Epigenetic regulation in RCC: opportunities for therapeutic intervention?

Improving the efficacy of targeted trials by multiple-marker analysis in castration-resistant prostate cancer (Citations: 1)

Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting (Citations: 2)


	View FAQ about top research areas and Fields of study

Rudolf Morant,Kantonsspital Saint Gallen,Oncology,Anatomy,Pharmacology

Publications (56) BibTeX | RIS | RefWorks Download

Cyclosporin-A therapy of pure red cell aplasia in a patient with B-cell chronic lymphocytic leukemia (Citations: 3)

Chemoprevention of breast and prostate cancers: where do we stand? (Citations: 2)

Quality of analgesic treatment in patients with advanced prostate cancer: do we do a better job now? The Swiss Group for Clinical Cancer Research (SAKK) experience (Citations: 1)

Improving the efficacy of targeted trials by multiple-marker analysis in castration-resistant prostate cancer (Citations: 1)

Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting (Citations: 2)

Publications (56)

BibTeX | RIS | RefWorks Download